Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events

Abstract Views: 1309
PDF: 1247
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

MPA is clinically administered as morfolinoethyl ester (mycophenolate mofetil, MMF) or, more recently, as a salt (enteric-coated mycophenolate sodium). It is a fermentation product of Penicillium brevicompactum and other analogue fungi, identified by Gosio in 1893 as a weak antibacterial agent; in 1969 Franklin and Cook discovered its capacity to inhibit the inosine mono phosphate dehydrogenase (IMPDH), an enzyme involved in purine nucleotide synthesis (1)...

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Zizzo, G., De Santis, M., & Ferraccioli, G. (2010). Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events. Reumatismo, 62(2), 91–100. https://doi.org/10.4081/reumatismo.2010.91